New Classifications of Five Distinct “Sleep” Profi... ...
Science in the Age of AI | AI for Science Forum...
Ask the Heart Doctor | Heart Valve Disease and Sur...
High-speed imaging tracks live brain cell activity...
NAD⁺ restores memory in Alzheimer's disease models...
Mark Cuban: A Master Disrupter for American Health...
Teen girls facing the most adversity showed the biggest gain...
September 15,2026
Specialized imaging reveals hormone-driven brain changes...
September 14,2026
Submillimeter MRI reveals brain hubs that guide risky decisi...
September 12,2026
Risk of herpes zoster among breast cancer survivors in Japan...
September 11,2026
Three proteins help organs tailor shared circadian clock to ...
September 10,2026
Should you worry about melatonin and heart failure? The evid...
December 02,2025
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
GOSH BRC Showcase 2025 - Genomic medicine...
Can a twice-a-year shot help end the HIV...
Announcement of the 2025 Nobel Prize in ...
Reprogramming Stem Cells Could Cure Type...
Why MDMA did NOT get FDA approval...
More News
Kirtane Highlights Uniqueness of Solid Tumor CAR T-Cell Agent A2B530

Kirtane Highlights Uniqueness of Solid Tumor CAR T-Cell Agent A2B530

For patients with solid tumors, investigators have faced hurdles replicating successes with chimeric antigen receptor (CAR) T-cell therapies. The novel CAR T-cell agent A2B530, looks to forge a pathwa
World medicine November 07,2023
Kirtane Highlights Uniqueness of Solid Tumor CAR T-Cell Agent A2B530

Kirtane Highlights Uniqueness of Solid Tumor CAR T-Cell Agent A2B530

For patients with solid tumors, investigators have faced hurdles replicating successes with chimeric antigen receptor (CAR) T-cell therapies. The novel CAR T-cell agent A2B530, looks to forge a pathwa
World medicine November 07,2023
From Mount Everest to your liver: The alarming reach of 'forever chemicals' in our environment and health

From Mount Everest to your liver: The alarming reach of 'forever chemicals' in our environment and health

In a recent review published in the journalScience of The Total Environment,researchers collate and discuss available literature on per- and polyfluoroalkyl substances (PFAS). They highlig
World medicine November 07,2023
From Mount Everest to your liver: The alarming reach of 'forever chemicals' in our environment and health

From Mount Everest to your liver: The alarming reach of 'forever chemicals' in our environment and health

In a recent review published in the journalScience of The Total Environment,researchers collate and discuss available literature on per- and polyfluoroalkyl substances (PFAS). They highlig
World medicine November 07,2023
INDIGO Trial Supports Vorasidenib as Effective Targeted Therapeutic in IDH1/2+ Low-Grade Glioma

INDIGO Trial Supports Vorasidenib as Effective Targeted Therapeutic in IDH1/2+ Low-Grade Glioma

Practice-changing safety and efficacy findings from the phase 3 INDIGO trial (NCT04164901) underscore the value of adding vorasidenib (AG-881) to the treatment armamentarium inIDH1/2-mutant glio
World medicine November 07,2023
INDIGO Trial Supports Vorasidenib as Effective Targeted Therapeutic in IDH1/2+ Low-Grade Glioma

INDIGO Trial Supports Vorasidenib as Effective Targeted Therapeutic in IDH1/2+ Low-Grade Glioma

Practice-changing safety and efficacy findings from the phase 3 INDIGO trial (NCT04164901) underscore the value of adding vorasidenib (AG-881) to the treatment armamentarium inIDH1/2-mutant glio
World medicine November 07,2023
Herrera Spotlights Key Research Across Hematologic Malignancies From the 2023 ASCO Annual Meeting

Herrera Spotlights Key Research Across Hematologic Malignancies From the 2023 ASCO Annual Meeting

Positive findings from thephase 3 SWOG S1826 trial(NCT03907488) have set the stage for ongoing efforts to align the treatment of adult and pediatric patients with newly diagnosed stage III
World medicine November 07,2023
Herrera Spotlights Key Research Across Hematologic Malignancies From the 2023 ASCO Annual Meeting

Herrera Spotlights Key Research Across Hematologic Malignancies From the 2023 ASCO Annual Meeting

Positive findings from thephase 3 SWOG S1826 trial(NCT03907488) have set the stage for ongoing efforts to align the treatment of adult and pediatric patients with newly diagnosed stage III
World medicine November 07,2023
AI-assisted smartphone app performs well in skin cancer diagnosis

AI-assisted smartphone app performs well in skin cancer diagnosis

Artificial intelligence (AI) is already widely used in medical diagnostics. An Austrian-Australian research team led by dermatologist Harald Kittler from MedUni Vienna investigated the extent to which
World medicine November 07,2023
AI-assisted smartphone app performs well in skin cancer diagnosis

AI-assisted smartphone app performs well in skin cancer diagnosis

Artificial intelligence (AI) is already widely used in medical diagnostics. An Austrian-Australian research team led by dermatologist Harald Kittler from MedUni Vienna investigated the extent to which
World medicine November 07,2023
FDA approves cord blood stem cell product for blood cancer patients

FDA approves cord blood stem cell product for blood cancer patients

The U.S. Food and Drug Administration approved Omisirge (omidubicel-onlv), a substantially modified allogeneic cord blood-based cell therapy, to cut the risk of infection in patients with blood cancer
World medicine November 07,2023
FDA approves cord blood stem cell product for blood cancer patients

FDA approves cord blood stem cell product for blood cancer patients

The U.S. Food and Drug Administration approved Omisirge (omidubicel-onlv), a substantially modified allogeneic cord blood-based cell therapy, to cut the risk of infection in patients with blood cancer
World medicine November 07,2023
FDA Accepts sBLA for Zanubrutinib Plus Obinutuzumab for R/R Follicular Lymphoma

FDA Accepts sBLA for Zanubrutinib Plus Obinutuzumab for R/R Follicular Lymphoma

The FDA has accepted a supplemental biologics license application (sBLA) seeking the approval of zanubrutinib (Brukinsa) in combination with obinutuzumab (Gazyva) in the treatment of adult patients wi
World medicine November 07,2023
FDA Accepts sBLA for Zanubrutinib Plus Obinutuzumab for R/R Follicular Lymphoma

FDA Accepts sBLA for Zanubrutinib Plus Obinutuzumab for R/R Follicular Lymphoma

The FDA has accepted a supplemental biologics license application (sBLA) seeking the approval of zanubrutinib (Brukinsa) in combination with obinutuzumab (Gazyva) in the treatment of adult patients wi
World medicine November 07,2023
City of Hope Ranks Among Nation’s Top 10 Best Hospitals for Cancer

City of Hope Ranks Among Nation’s Top 10 Best Hospitals for Cancer

City of Hope was recognized as the eighth “Best Hospital” for cancer in the nation, according to U.S. News & World Report’s 2023-24 Best Hospitals: Specialty Ranking. This marks the second consecu
World medicine November 07,2023
City of Hope Ranks Among Nation’s Top 10 Best Hospitals for Cancer

City of Hope Ranks Among Nation’s Top 10 Best Hospitals for Cancer

City of Hope was recognized as the eighth “Best Hospital” for cancer in the nation, according to U.S. News & World Report’s 2023-24 Best Hospitals: Specialty Ranking. This marks the second consecu
World medicine November 07,2023
Wholegrains give kids a heart-healthy boost, says new Danish study

Wholegrains give kids a heart-healthy boost, says new Danish study

In a recent study published inThe American Journal of Clinical Nutrition,researchers compared the cardiovascular outcomes of refined grains to wholegrains in children. Their randomized cro
World medicine November 07,2023
Wholegrains give kids a heart-healthy boost, says new Danish study

Wholegrains give kids a heart-healthy boost, says new Danish study

In a recent study published inThe American Journal of Clinical Nutrition,researchers compared the cardiovascular outcomes of refined grains to wholegrains in children. Their randomized cro
World medicine November 07,2023
Personalized colorectal cancer screening reduces low-value care in older adults

Personalized colorectal cancer screening reduces low-value care in older adults

Colorectal cancer screening is widely recommended for adults ages 45 to 75 with an average risk of developing the disease. However, many people don't realize that the benefits of screening for thi
World medicine November 07,2023
Personalized colorectal cancer screening reduces low-value care in older adults

Personalized colorectal cancer screening reduces low-value care in older adults

Colorectal cancer screening is widely recommended for adults ages 45 to 75 with an average risk of developing the disease. However, many people don't realize that the benefits of screening for thi
World medicine November 07,2023
More News
Week’s Top
Podcasts
... Health spending has been rising across rich countries with different systems ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... At what age do people experience depression for the first time? Depression can affect people over long periods of their lives. Some people experience this condition continuously, while for others, it occu...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com